ISCT 2022 NEWS
ISCT22: Children's National sees improved cell therapy potency, quicker patient delivery
May 9, 2022 -- Children's National Hospital in Washington, DC, is seeing improvements in the potency of existing cell therapies and a reduction in the time it takes to get them to patients, according to Patrick Hanley, PhD, chief and director of the pediatric medical center’s Cellular Therapy Program. Hanley spoke with ScienceBoard.net at the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting in San Francisco.
May 9, 2022 -- Children's National Hospital in Washington, DC, is seeing improvements in the potency of existing cell therapies and a reduction in the time it takes to get them to patients, according to Patrick Hanley, PhD, chief and director of the pediatric medical center’s Cellular Therapy Program. Hanley spoke with ScienceBoard.net at the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting in San Francisco.
ISCT22: Orgenesis looks to simplify, lower costs of providing CGT therapies
May 9, 2022 -- Personalized cell and gene therapies (CGTs) offer the potential to address the most challenging diseases, Vered Caplan, CEO of biotech company Orgenesis, told ScienceBoard.net at the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting in San Francisco. However, several factors make CGTs complex, expensive, and difficult to bring to market, including small/personalized batch production and the fact that everything must be conducted in a very sterile environment.
May 9, 2022 -- Personalized cell and gene therapies (CGTs) offer the potential to address the most challenging diseases, Vered Caplan, CEO of biotech company Orgenesis, told ScienceBoard.net at the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting in San Francisco. However, several factors make CGTs complex, expensive, and difficult to bring to market, including small/personalized batch production and the fact that everything must be conducted in a very sterile environment.
ISCT22: BroadOak’s Poltilove remains bullish on CGT market despite downturn
May 9, 2022 -- Bryan Poltilove, partner at BroadOak Capital Partners, spoke with ScienceBoard.net at the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting in San Francisco about how BroadOak’s medium- to long-term investment strategy sees “great science” happening in the sector that’s improving productivity and advancing cell and gene therapies (CGTs), biologics, and other modalities.
May 9, 2022 -- Bryan Poltilove, partner at BroadOak Capital Partners, spoke with ScienceBoard.net at the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting in San Francisco about how BroadOak’s medium- to long-term investment strategy sees “great science” happening in the sector that’s improving productivity and advancing cell and gene therapies (CGTs), biologics, and other modalities.
ISCT22: Cell therapy has potential to address unmet medical needs in orthopedics
May 6, 2022 -- Miguel Forte, CEO of Bone Therapeutics, and president-elect of the International Society for Cell & Gene Therapy (ISCT), spoke with ScienceBoard.net at the ISCT 2022 annual meeting in San Francisco about regenerative medicine and orthopedics.
May 6, 2022 -- Miguel Forte, CEO of Bone Therapeutics, and president-elect of the International Society for Cell & Gene Therapy (ISCT), spoke with ScienceBoard.net at the ISCT 2022 annual meeting in San Francisco about regenerative medicine and orthopedics.
ISCT working group weighs in on expanded access to CGT
May 6, 2022 -- Patricia Zettler, JD, associate professor of law at The Ohio State University, and chair of the International Society for Cell & Gene Therapy (ISCT) Expanded Access Working Group, spoke with ScienceBoard.net at the ISCT 2022 annual meeting in San Francisco about the regulatory and ethical issues around cell and gene therapy (CGT) expanded access.
May 6, 2022 -- Patricia Zettler, JD, associate professor of law at The Ohio State University, and chair of the International Society for Cell & Gene Therapy (ISCT) Expanded Access Working Group, spoke with ScienceBoard.net at the ISCT 2022 annual meeting in San Francisco about the regulatory and ethical issues around cell and gene therapy (CGT) expanded access.
ISCT president calls for cell and gene therapy education, training amid ‘talent shortage’
May 6, 2022 -- This week in San Francisco, industry, investors, physicians, patients, and regulators convened at the International Society for Cell & Gene Therapy (ISCT) annual meeting. ISCT President Bruce Levine, PhD, professor of cancer gene therapy at the University of Pennsylvania, spoke with ScienceBoard.net at ISCT 2022 about the status and future of the field of cell and gene therapy.
May 6, 2022 -- This week in San Francisco, industry, investors, physicians, patients, and regulators convened at the International Society for Cell & Gene Therapy (ISCT) annual meeting. ISCT President Bruce Levine, PhD, professor of cancer gene therapy at the University of Pennsylvania, spoke with ScienceBoard.net at ISCT 2022 about the status and future of the field of cell and gene therapy.
ISCT22: Tackling the ethical issues around cell and gene therapy
May 5, 2022 -- Unproven and unethical cell and gene therapies are a growing problem worldwide, according to Laertis Ikonomou, PhD, of the Department of Oral Biology at the University of Buffalo, and chair of the International Society for Cell & Gene Therapy (ISCT) Committee on the Ethics of Cell and Gene Therapy. Ikonomou spoke with ScienceBoard.net at the ISCT 2022 annual meeting in San Francisco this week.
May 5, 2022 -- Unproven and unethical cell and gene therapies are a growing problem worldwide, according to Laertis Ikonomou, PhD, of the Department of Oral Biology at the University of Buffalo, and chair of the International Society for Cell & Gene Therapy (ISCT) Committee on the Ethics of Cell and Gene Therapy. Ikonomou spoke with ScienceBoard.net at the ISCT 2022 annual meeting in San Francisco this week.